Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Imatinib Mesylate × Other neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 113 Myeloid 78 Sarcoma 46 Gastrointestinal 39 Lymphoid 29 Thoracic 15 CNS 13 Other solid neoplasm 10 Genitourinary 10 Dermatologic 10 Tumor-Agnostic 7 Head & Neck 7 Gynecologic 4 Breast 4 Endocrine 2 Plasma cell 1 Other neoplasm 1 Other 1 Classical hematology 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Cyclophosphamide 9 Surveys and Questionnaires 8 fludarabine phosphate 6 Whole-Body Irradiation 6 Peripheral Blood Stem Cell Transplantation 6 Busulfan 6 Methotrexate 5 Educational Status 5 Early Intervention, Educational 5 Tacrolimus 4 Mycophenolic Acid 4 Methods 4 Interviews as Topic 4 Immunohistochemistry 4 Gene Expression Profiling 4 Epoetin Alfa 4 Decitabine 4 Cyclosporine 4 Celecoxib 4 Biopsy 4 Antilymphocyte Serum 4 fludarabine 3 Sirolimus 3 Radiotherapy 3 Melphalan 3 Imiquimod 3 Fentanyl 3 Etoposide 3 Endoscopic Mucosal Resection 3 Darbepoetin alfa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡